loading
Ideaya Biosciences Inc stock is traded at $25.03, with a volume of 1.23M. It is up +5.80% in the last 24 hours and up +14.78% over the past month. IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$23.63
Open:
$23.83
24h Volume:
1.23M
Relative Volume:
1.05
Market Cap:
$2.19B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-11.43
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
+13.17%
1M Performance:
+14.78%
6M Performance:
+5.84%
1Y Performance:
-40.77%
1-Day Range:
Value
$23.57
$25.54
1-Week Range:
Value
$21.33
$25.54
52-Week Range:
Value
$13.45
$44.42

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
Name
Ideaya Biosciences Inc
Name
Phone
650-443-6209
Name
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
Employee
131
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
IDYA's Discussions on Twitter

Compare IDYA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IDYA
Ideaya Biosciences Inc
25.05 1.93B 23.38M -155.22M -134.36M -2.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.92 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
569.73 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.27 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
587.20 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.89 31.99B 3.81B -644.79M -669.77M -6.24

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-22-25 Initiated TD Cowen Buy
Jul-10-25 Resumed Goldman Neutral
Jun-26-25 Initiated Wells Fargo Overweight
Nov-18-24 Initiated Stephens Overweight
Nov-05-24 Downgrade Leerink Partners Outperform → Market Perform
Oct-24-24 Initiated UBS Buy
Oct-15-24 Initiated Cantor Fitzgerald Overweight
Jul-08-24 Initiated Mizuho Outperform
Mar-08-24 Initiated BTIG Research Buy
Aug-08-23 Initiated SVB Securities Outperform
May-24-23 Initiated Goldman Buy
Apr-24-23 Upgrade Stifel Hold → Buy
Mar-23-23 Initiated Berenberg Buy
Feb-28-23 Initiated RBC Capital Mkts Outperform
Dec-28-22 Initiated CapitalOne Overweight
Oct-27-22 Initiated Citigroup Buy
Aug-15-22 Downgrade Stifel Buy → Hold
Jul-18-22 Resumed Oppenheimer Outperform
Mar-10-22 Upgrade Stifel Hold → Buy
Sep-23-21 Initiated Stifel Hold
Jun-04-21 Resumed Robert W. Baird Outperform
Mar-11-21 Initiated Guggenheim Buy
Oct-07-20 Initiated Wedbush Outperform
Sep-01-20 Initiated Northland Capital Outperform
Jul-13-20 Upgrade JP Morgan Neutral → Overweight
Jun-17-20 Reiterated H.C. Wainwright Buy
Apr-06-20 Initiated H.C. Wainwright Buy
Mar-13-20 Initiated ROTH Capital Buy
Oct-17-19 Initiated Oppenheimer Outperform
Sep-10-19 Initiated Robert W. Baird Outperform
Jun-17-19 Initiated Citigroup Buy
Jun-17-19 Initiated JP Morgan Neutral
Jun-17-19 Initiated Jefferies Buy
View All

Ideaya Biosciences Inc Stock (IDYA) Latest News

pulisher
09:36 AM

IDEAYA to present phase 2 data on uveal melanoma drug at ESMO By Investing.com - Investing.com South Africa

09:36 AM
pulisher
09:25 AM

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - Yahoo Finance

09:25 AM
pulisher
Jul 23, 2025

What drives IDEAYA Biosciences Inc. stock priceRobust financial gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about IDEAYA Biosciences Inc. stockFree Investment Portfolio Suggestions - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

IDEAYA Biosciences: Precision Oncology Pipeline and Synthetic Lethality Catalysts - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

IDEAYA's First-in-Class Cancer Pipeline: Major Clinical Updates Coming at 10th Anniversary R&D Day - Stock Titan

Jul 23, 2025
pulisher
Jul 23, 2025

Signaturefd LLC Increases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Jul 23, 2025
pulisher
Jul 23, 2025

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - The Malaysian Reserve

Jul 23, 2025
pulisher
Jul 23, 2025

Is IDEAYA Biosciences Inc. a good long term investmentRobust financial gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

IDEAYA Biosciences Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Breakthrough Lung Cancer Drug IDE849 Shows First Human Results: 70+ Patient Data Coming at WCLC 2025 - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.

Jul 22, 2025
pulisher
Jul 22, 2025

symbol__ Stock Quote Price and Forecast - CNN

Jul 22, 2025
pulisher
Jul 22, 2025

IDEAYA Biosciences: TD Cowen initiates coverage with Buy rating. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

TD Cowen initiates Ideaya Biosciences stock with Buy rating By Investing.com - Investing.com Canada

Jul 22, 2025
pulisher
Jul 21, 2025

autocarpro> 2025> What analysts say about IDEAYA Biosciences Inc. stockPhenomenal trading returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan

Jul 21, 2025
pulisher
Jul 19, 2025

Teacher Retirement System of Texas Cuts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Jul 19, 2025
pulisher
Jul 16, 2025

(IDYA) Proactive Strategies - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 15, 2025

Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionROI Driven Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How IDEAYA Biosciences Inc. stock performs during market volatilityDaily Stock Radar - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $47.55 - Defense World

Jul 14, 2025
pulisher
Jul 12, 2025

The Goldman Sachs Group Upgrades IDEAYA Biosciences (NASDAQ:IDYA) to “Hold” - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Royal Bank Of Canada - Defense World

Jul 11, 2025
pulisher
Jul 11, 2025

Ideaya Biosciences stock gets Neutral rating from Goldman Sachs By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Ideaya Biosciences shares fall 2.68% intraday as Biocytogen Pharmaceuticals enters into a global licensing agreement with BeOne Medicines. - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛

Jul 10, 2025
pulisher
Jul 09, 2025

Ideaya Biosciences stock price target lowered to $30 by RBC Capital - Investing.com Canada

Jul 09, 2025

Ideaya Biosciences Inc Stock (IDYA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.55
price up icon 3.00%
$36.54
price up icon 1.43%
$103.30
price down icon 0.21%
$27.25
price down icon 3.00%
$113.95
price down icon 0.57%
biotechnology ONC
$295.88
price up icon 0.27%
Cap:     |  Volume (24h):